301122.SZ
采纳股份
SZSE · Healthcare · C 制造业 · CN
CNY 39.00
−1.27%Aug 26, 2026, 08:20 UTC
Haixiang Pharmaceutical's wholly-owned subsidiary Zhejiang Haixiang Chuannan Pharmaceutical received approval from China's National Medical Products Administration for its adenosine cyclophosphate API, packaged in 4kg/drum, with registration approved but GMP compliance check still required before domestic production and sales.
Source:Aug 26, 2026, 07:59 UTC
Cainiao Co., Ltd.'s wholly-owned subsidiary Jiangsu Cainiao Medical Technology Co., Ltd. received a Class III medical device registration certificate from China's National Medical Products Administration for a disposable human arterial blood sample collector, valid until August 23, 2031.
Source:Aug 19, 2026, 10:17 UTC
Shareholders of Caijia Co., Ltd. signed a supplementary agreement to adjust the payment terms for the transfer of 22.011 million shares (18.01% of total share capital) to Paitai Pharmaceutical, with the fourth installment payment due no later than 30 working days after the share transfer registration.
Source:Jul 29, 2026, 09:56 UTC
Caibon shares and its wholly-owned subsidiaries plan to use up to 800 million yuan of idle self-owned funds to purchase principal-guaranteed floating-income RMB structured deposits and other low-risk products, with a term of 12 months and can be used on a rolling basis.
Source: